TIK-301 (LY-156735) is an agonist for the melatonin receptors MT1 and MT2 that is under development for the treatment of insomnia and other sleep disorders.

[2][3] In July 2007, the open Investigational New Drug (IND) was transferred to Tikvah Therapeutics Inc. in Atlanta, GA by Phase II Discovery, where it was renamed to TIK-301.

[16] The sleep latency improvement at the 100 mg dose is comparable to FDA approved zolpidem's effects.

Because of its affinity for serotonin receptors, it has potential to serve as a possible antidepressant drug, similar to agomelatine.

[8][9][19] TIK-301 has also been considered for use in patients with mild cognitive impairment (MCI) because of sleep disorder prevalence.

[15] TIK-301, as well as other melatonin agonists, has been reported to have potential in preventing or treating urinary incontinence, but have not been tested in humans for this purpose.

[16] A few patients reported cases of somnolence in clinical trials, which is consistent with the drug's soporific effects.

[13] Because of its receptor specific action, there are no associated changes in core body temperatures, heart rate or blood pressure as with other melatonin medications.